RIPK1-IN-7
Based on 1 Customer Validation
RIPK1-IN-7 is a potent and selective RIPK1 inhibitor with a Kd of 4 nM and an enzymatic IC50 of 11 nM. RIPK1-IN-7 exhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model.
For research use only. We do not sell to patients.
- Purity: 98.56%
- CAS No.: 2300982-44-7
- Formula: C25H22F3N5O2
- Molecular Weight:481.47
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Kinase Inhibitor Library
HY-L009
-
NF-κB Signaling Compound Library
HY-L014
-
Anti-Cancer Compound Library
HY-L025
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| J774.A1 | EC50 |
0.517 nM
Compound: 22b
|
Cytoprotection against TNFalpha/Smac-mimetic/z-VAD-FMK induced necroptosis in mouse J774A.1 cells after 24 hrs by CCK-8 assay
Cytoprotection against TNFalpha/Smac-mimetic/z-VAD-FMK induced necroptosis in mouse J774A.1 cells after 24 hrs by CCK-8 assay
|
[PMID: 30480444] |
| L929 | EC50 |
0.999 nM
Compound: 22b
|
Cytoprotection against TNFalpha/z-VAD-FMK induced necroptosis in mouse L929 cells after 24 hrs by CCK-8 assay
Cytoprotection against TNFalpha/z-VAD-FMK induced necroptosis in mouse L929 cells after 24 hrs by CCK-8 assay
|
[PMID: 30480444] |
| U-937 | EC50 |
11.55 nM
Compound: 22b
|
Cytoprotection against TNFalpha/Smac-mimetic/z-VAD-FMK induced necroptosis in human U937 cells after 24 hrs by CCK-8 assay
Cytoprotection against TNFalpha/Smac-mimetic/z-VAD-FMK induced necroptosis in human U937 cells after 24 hrs by CCK-8 assay
|
[PMID: 30480444] |
RIPK1-IN-7 shows potent cell protection effect in the TSZ-induced HT29 cell necroptosis model with an EC50 of 2nM[1].
RIPK1-IN-7 displays considerable activity against several other kinases, such as Flt4, TrkA, TrkB, TrkC, Axl, HRI, Mer, and MAP4K5 with IC50s of 20, 26, 8, 7, 35, 26, 29, and 27 nM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2300982-44-7
-
Appearance Solid
-
Molecular Weight 481.47
-
Formula C25H22F3N5O2
-
Color Light yellow to yellow
-
SMILES
NC1=C2C(N(CC)C=C2C3=CC(CCN4C(CC5=CC=CC(OC(F)(F)F)=C5)=O)=C4C=C3)=NC=N1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvent & Solubility
DMSO : 62.5 mg/mL (129.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0770 mL | 10.3849 mL | 20.7697 mL | 51.9243 mL |
| 5 mM | 0.4154 mL | 2.0770 mL | 4.1539 mL | 10.3849 mL | |
| 10 mM | 0.2077 mL | 1.0385 mL | 2.0770 mL | 5.1924 mL | |
| 15 mM | 0.1385 mL | 0.6923 mL | 1.3846 mL | 3.4616 mL | |
| 20 mM | 0.1038 mL | 0.5192 mL | 1.0385 mL | 2.5962 mL | |
| 25 mM | 0.0831 mL | 0.4154 mL | 0.8308 mL | 2.0770 mL | |
| 30 mM | 0.0692 mL | 0.3462 mL | 0.6923 mL | 1.7308 mL | |
| 40 mM | 0.0519 mL | 0.2596 mL | 0.5192 mL | 1.2981 mL | |
| 50 mM | 0.0415 mL | 0.2077 mL | 0.4154 mL | 1.0385 mL | |
| 60 mM | 0.0346 mL | 0.1731 mL | 0.3462 mL | 0.8654 mL | |
| 80 mM | 0.0260 mL | 0.1298 mL | 0.2596 mL | 0.6491 mL | |
| 100 mM | 0.0208 mL | 0.1038 mL | 0.2077 mL | 0.5192 mL |
RIPK1-IN-7 Related Classifications
HY-119933 Related Classifications
Powered by Bioz